341 related articles for article (PubMed ID: 34250504)
1. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy.
Jeha S; Choi J; Roberts KG; Pei D; Coustan-Smith E; Inaba H; Rubnitz JE; Ribeiro RC; Gruber TA; Raimondi SC; Karol SE; Qu C; Brady SW; Gu Z; Yang JJ; Cheng C; Downing JR; Evans WE; Relling MV; Campana D; Mullighan CG; Pui CH
Blood Cancer Discov; 2021 Jul; 2(4):326-337. PubMed ID: 34250504
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia.
Yu CH; Jou ST; Su YH; Coustan-Smith E; Wu G; Cheng CN; Lu MY; Lin KH; Wu KH; Chen SH; Huang FL; Chang HH; Wang JL; Yen HJ; Li MJ; Chou SW; Ho WL; Liu YL; Chang CC; Lin ZS; Lin CY; Chen HY; Ni YL; Lin DT; Lin SW; Yang JJ; Ni YH; Pui CH; Yu SL; Yang YL
Cancer; 2023 Mar; 129(5):790-802. PubMed ID: 36537587
[TBL] [Abstract][Full Text] [Related]
3. Emerging molecular subtypes and therapies in acute lymphoblastic leukemia.
Davis K; Sheikh T; Aggarwal N
Semin Diagn Pathol; 2023 May; 40(3):202-215. PubMed ID: 37120350
[TBL] [Abstract][Full Text] [Related]
4. Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.
Paietta E; Roberts KG; Wang V; Gu Z; Buck GAN; Pei D; Cheng C; Levine RL; Abdel-Wahab O; Cheng Z; Wu G; Qu C; Shi L; Pounds S; Willman CL; Harvey R; Racevskis J; Barinka J; Zhang Y; Dewald GW; Ketterling RP; Alejos D; Lazarus HM; Luger SM; Foroni L; Patel B; Fielding AK; Melnick A; Marks DI; Moorman AV; Wiernik PH; Rowe JM; Tallman MS; Goldstone AH; Mullighan CG; Litzow MR
Blood; 2021 Sep; 138(11):948-958. PubMed ID: 33895809
[TBL] [Abstract][Full Text] [Related]
5. High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Lee JW; Kim Y; Cho B; Kim S; Jang PS; Lee J; Cho H; Lee GD; Chung NG; Kim M
Cancer Med; 2020 Jul; 9(13):4632-4639. PubMed ID: 32378810
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
7. Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia.
Li Z; Lee SHR; Chin WHN; Lu Y; Jiang N; Lim EH; Coustan-Smith E; Chiew KH; Oh BLZ; Koh GS; Chen Z; Kham SKY; Quah TC; Lin HP; Tan AM; Ariffin H; Yang JJ; Yeoh AE
Blood Adv; 2021 Dec; 5(23):5226-5238. PubMed ID: 34547766
[TBL] [Abstract][Full Text] [Related]
8. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
[TBL] [Abstract][Full Text] [Related]
9. Updates on lymphoblastic leukemia/lymphoma classification and minimal/measurable residual disease analysis.
Kovach AE; Wood BL
Semin Diagn Pathol; 2023 Nov; 40(6):457-471. PubMed ID: 37953192
[TBL] [Abstract][Full Text] [Related]
10. Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on
Hrabovsky S; Vrzalova Z; Stika J; Jelinkova H; Jarosova M; Navrkalova V; Martenek J; Folber F; Salek C; Horacek JM; Pospisilova S; Mayer J; Doubek M
Acta Oncol; 2021 Jun; 60(6):760-770. PubMed ID: 33750258
[TBL] [Abstract][Full Text] [Related]
11. Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort.
Zaliova M; Stuchly J; Winkowska L; Musilova A; Fiser K; Slamova M; Starkova J; Vaskova M; Hrusak O; Sramkova L; Stary J; Zuna J; Trka J
Haematologica; 2019 Jul; 104(7):1396-1406. PubMed ID: 30630978
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Two Quantitative PCR-Based Assays for Detection of Minimal Residual Disease in B-Precursor Acute Lymphoblastic Leukemia Harboring Three Major Fusion Transcripts.
Huang YJ; Kuo MC; Jaing TH; Liu HC; Yeh TC; Chen SH; Lin TL; Yang CP; Wang PN; Sheen JM; Chang TK; Chang CH; Hu SF; Huang TY; Wang SC; Wu KH; Chiou SS; Hsiao CC; Shih LY
J Mol Diagn; 2021 Oct; 23(10):1373-1379. PubMed ID: 34325057
[TBL] [Abstract][Full Text] [Related]
13. Classification and genetics of pediatric B-other acute lymphoblastic leukemia by targeted RNA sequencing.
Migita NA; Jotta PY; Nascimento NPD; Vasconcelos VS; Centoducatte GL; Massirer KB; Azevedo AC; Brandalise SR; Yunes JA
Blood Adv; 2023 Jul; 7(13):2957-2971. PubMed ID: 36848637
[TBL] [Abstract][Full Text] [Related]
14. Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia.
Burmeister T; Gökbuget N; Schwartz S; Fischer L; Hubert D; Sindram A; Hoelzer D; Thiel E
Haematologica; 2010 Feb; 95(2):241-6. PubMed ID: 19713226
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of next-generation sequencing for measurable residual disease monitoring in three major fusion transcript subtypes of B-precursor acute lymphoblastic leukaemia.
Huang YJ; Chen SH; Liu HC; Jaing TH; Yeh TC; Kuo MC; Lin TL; Chen CC; Wang SC; Chang TK; Hsiao CC; Liang DC; Shih LY
Pathology; 2024 Apr; ():. PubMed ID: 38719770
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
Roberts KG; Pei D; Campana D; Payne-Turner D; Li Y; Cheng C; Sandlund JT; Jeha S; Easton J; Becksfort J; Zhang J; Coustan-Smith E; Raimondi SC; Leung WH; Relling MV; Evans WE; Downing JR; Mullighan CG; Pui CH
J Clin Oncol; 2014 Sep; 32(27):3012-20. PubMed ID: 25049327
[TBL] [Abstract][Full Text] [Related]
17. The role of minimal residual disease in specific subtypes of pediatric acute lymphoblastic leukemia.
Xue YJ; Wang Y; Jia YP; Zuo YX; Wu J; Lu AD; Zhang LP
Int J Hematol; 2021 Apr; 113(4):547-555. PubMed ID: 33386596
[TBL] [Abstract][Full Text] [Related]
18. Sequential Approach to Improve the Molecular Classification of Childhood Acute Lymphoblastic Leukemia.
Yu CH; Wu G; Chang CC; Jou ST; Lu MY; Lin KH; Chen SH; Wu KH; Huang FL; Cheng CN; Chang HH; Hedges D; Wang JL; Yen HJ; Li MJ; Chou SW; Hung CT; Lin ZS; Lin CY; Chen HY; Ni YL; Hsu YC; Lin DT; Lin SW; Yang JJ; Pui CH; Yu SL; Yang YL
J Mol Diagn; 2022 Nov; 24(11):1195-1206. PubMed ID: 35963521
[TBL] [Abstract][Full Text] [Related]
19. Molecular markers in ALL: Clinical implications.
Kimura S; Mullighan CG
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101193. PubMed ID: 33038982
[TBL] [Abstract][Full Text] [Related]
20. Transcriptome Sequencing Allows Comprehensive Genomic Characterization of Pediatric B-Acute Lymphoblastic Leukemia in an Academic Clinical Laboratory.
Hu Z; Kovach AE; Yellapantula V; Ostrow D; Doan A; Ji J; Schmidt RJ; Gu Z; Bhojwani D; Raca G
J Mol Diagn; 2024 Jan; 26(1):49-60. PubMed ID: 37981088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
